Opus Genetics, Inc.(IRD) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal diseases (IRDs) The pro forma cash balance of the combined company was approximately $37 million as of September 30, 2024 (preliminary and unaudited), expected to extend runway into 2026 Four clinical data readouts expected in 2 ...